Literature DB >> 26733436

Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung.

Isha Verma1, Anar Modi2, Hemantkumar Tripathi3, Abhinav Agrawal1.   

Abstract

Thyroiditis is characterised by transient hyperthyroidism, followed sometimes by hypothyroidism, and then recovery. We report a case of painless drug-induced thyroiditis-in a patient with no history of any thyroid disorder-treated with Nivolumab (an IgG4 monoclonal antibody against Programmed Death Receptor 1). The purpose of this case report is to increase awareness among clinicians regarding this possible adverse effect from Nivolumab, and discuss the possible pathophysiology and management strategies in such patients. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26733436      PMCID： PMC4716348          DOI： 10.1136/bcr-2015-213692

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  14 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease.

Authors:  A Colao; R Pivonello; A Faggiano; M Filippella; D Ferone; C Di Somma; G Cerbone; P Marzullo; G Fenzi; G Lombardi
Journal:  Clin Endocrinol (Oxf)       Date:  2000-07       Impact factor: 3.478

Review 3.  Thyroid emergencies.

Authors:  Nicholas J Sarlis; Loukas Gourgiotis
Journal:  Rev Endocr Metab Disord       Date:  2003-05       Impact factor: 6.514

Review 4.  Thyroiditis.

Authors:  Elizabeth N Pearce; Alan P Farwell; Lewis E Braverman
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

Review 5.  Mitigating the toxic effects of anticancer immunotherapy.

Authors:  Tara C Gangadhar; Robert H Vonderheide
Journal:  Nat Rev Clin Oncol       Date:  2014-01-21       Impact factor: 66.675

Review 6.  Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.

Authors:  Mabel Ryder; Margaret Callahan; Michael A Postow; Jedd Wolchok; James A Fagin
Journal:  Endocr Relat Cancer       Date:  2014-03-07       Impact factor: 5.678

Review 7.  Toxicity patterns with immunomodulating antibodies and their combinations.

Authors:  John B A G Haanen; Hans van Thienen; Christian U Blank
Journal:  Semin Oncol       Date:  2015-02-14       Impact factor: 4.929

8.  Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab.

Authors:  Tomohiko Narita; Naoki Oiso; Yasunori Taketomo; Kazunori Okahashi; Kohei Yamauchi; Masako Sato; Shusuke Uchida; Hiromasa Matsuda; Akira Kawada
Journal:  J Dermatol       Date:  2015-07-22       Impact factor: 4.005

9.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

10.  Post-partum transient thyrotoxicosis with painless thyroiditis.

Authors:  J Ginsberg; P G Walfish
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321
View more
  6 in total

Review 1.  Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Authors:  David J Byun; Jedd D Wolchok; Lynne M Rosenberg; Monica Girotra
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

2.  Urgent Need to Define Pretreatment Predictors of Immune Check Point Inhibitors Related Endocrinopathies: A Case Report and Review of Literature.

Authors:  Vishal Sehgal; Richard Childress
Journal:  J Transl Int Med       Date:  2017-12-29

Review 3.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

4.  Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.

Authors:  Xiaoying Sun; Raheleh Roudi; Ting Dai; Shangya Chen; Bin Fan; Hongjin Li; Yaqiong Zhou; Min Zhou; Bo Zhu; Chengqian Yin; Bin Li; Xin Li
Journal:  BMC Cancer       Date:  2019-06-10       Impact factor: 4.430

Review 5.  Thyroid disorders induced by checkpoint inhibitors.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Fabio Galetta; Emanuele Citi; Salvatore Benvenga; Alessandro Antonelli
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 9.306

6.  Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.

Authors:  Tomoko Kobayashi; Shintaro Iwama; Yoshinori Yasuda; Norio Okada; Taku Tsunekawa; Takeshi Onoue; Hiroshi Takagi; Daisuke Hagiwara; Yoshihiro Ito; Yoshiaki Morishita; Motomitsu Goto; Hidetaka Suga; Ryoichi Banno; Kenji Yokota; Tetsunari Hase; Masahiro Morise; Naozumi Hashimoto; Masahiko Ando; Hitoshi Kiyoi; Momokazu Gotoh; Yuichi Ando; Masashi Akiyama; Yoshinori Hasegawa; Hiroshi Arima
Journal:  J Endocr Soc       Date:  2018-02-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.